You are here

Semin Liver Dis DOI:10.1055/s-0030-1247131

Molecular classification and novel targets in hepatocellular carcinoma: recent advancements.

Publication TypeJournal Article
Year of Publication2010
AuthorsHoshida, Y, Toffanin, S, Lachenmayer, A, Villanueva, A, Minguez, B, Llovet, JM
JournalSemin Liver Dis
Date Published2010 Feb
KeywordsAntineoplastic Agents, Biomarkers, Tumor, Carcinoma, Hepatocellular, Drug Delivery Systems, Gene Expression Regulation, Neoplastic, Humans, Liver Neoplasms, Neovascularization, Pathologic, Prognosis, RNA, Messenger, Signal Transduction

Hepatocellular carcinoma (HCC) is one of most lethal cancers worldwide. Strategic decisions for the advancement of molecular therapies in this neoplasm require a clear understanding of its molecular classification. Studies indicate aberrant activation of signaling pathways involved in cellular proliferation (e.g., epidermal growth factor and RAS/mitogen-activated protein kinase pathways), survival (e.g., Akt/mechanistic target of rapamycin pathway), differentiation (e.g., Wnt and Hedgehog pathways), and angiogenesis (e.g., vascular endothelial growth factor and platelet-derived growth factor), which is heterogeneously presented in each tumor. Integrative analysis of accumulated genomic datasets has revealed a global scheme of molecular classification of HCC tumors observed across diverse etiologic factors and geographic locations. Such a framework will allow systematic understanding of the frequently co-occurring molecular aberrations to design treatment strategy for each specific subclass of tumors. Accompanied by a growing number of clinical trials of molecular targeted drugs, diagnostic and prognostic biomarker development will be facilitated with special attention on study design and with new assay technologies specialized for archived fixed tissues. A new class of genomic information, microRNA dysregulation and epigenetic alterations, will provide insight for more precise understanding of disease mechanism and expand the opportunity of biomarker/therapeutic target discovery. These efforts will eventually enable personalized management of HCC.


Alternate JournalSemin. Liver Dis.
PubMed ID20175032
PubMed Central IDPMC3668687
Grant ListP20 AA017067 / AA / NIAAA NIH HHS / United States
R01 DK037340 / DK / NIDDK NIH HHS / United States
R01 DK056601 / DK / NIDDK NIH HHS / United States
R01 DK076986 / DK / NIDDK NIH HHS / United States